PharmaCyte Biotech is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April. At present, PharmaCyte Biotech's Other Current Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Total Current Liabilities is expected to grow to about 9 M, whereas Retained Earnings are projected to grow to (98.9 M). Key indicators impacting PharmaCyte Biotech's financial strength include:
The essential information of the day-to-day investment outlook for PharmaCyte Biotech includes many different criteria found on its balance sheet. An individual investor should monitor PharmaCyte Biotech's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in PharmaCyte Biotech.
Please note, the presentation of PharmaCyte Biotech's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, PharmaCyte Biotech's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of PharmaCyte Biotech's management manipulating its earnings.
PharmaCyte Biotech Stock Summary
PharmaCyte Biotech competes with Kezar Life, Invivyd, Spruce Biosciences, Y MAbs, and Shattuck Labs. PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada. Pharmacyte Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 4 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining PharmaCyte Biotech's current stock value. Our valuation model uses many indicators to compare PharmaCyte Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across PharmaCyte Biotech competition to find correlations between indicators driving PharmaCyte Biotech's intrinsic value. More Info.
PharmaCyte Biotech is considered to be number one stock in return on equity category among its peers. It is regarded second in return on asset category among its peers . At present, PharmaCyte Biotech's Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the PharmaCyte Biotech's earnings, one of the primary drivers of an investment's value.
PharmaCyte Biotech Systematic Risk
PharmaCyte Biotech's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. PharmaCyte Biotech volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on PharmaCyte Biotech correlated with the market. If Beta is less than 0 PharmaCyte Biotech generally moves in the opposite direction as compared to the market. If PharmaCyte Biotech Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one PharmaCyte Biotech is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of PharmaCyte Biotech is generally in the same direction as the market. If Beta > 1 PharmaCyte Biotech moves generally in the same direction as, but more than the movement of the benchmark.
About PharmaCyte Biotech Financials
What exactly are PharmaCyte Biotech Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include PharmaCyte Biotech's income statement, its balance sheet, and the statement of cash flows. Potential PharmaCyte Biotech investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although PharmaCyte Biotech investors may use each financial statement separately, they are all related. The changes in PharmaCyte Biotech's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on PharmaCyte Biotech's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
Today, most investors in PharmaCyte Biotech Stock are looking for potential investment opportunities by analyzing not only static indicators but also various PharmaCyte Biotech's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of PharmaCyte Biotech growth as a starting point in their analysis.
Price Earnings To Growth Ratio
0.0801
At present, PharmaCyte Biotech's Price Earnings To Growth Ratio is projected to slightly grow based on the last few years of reporting.
PharmaCyte Biotech March 22, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of PharmaCyte Biotech help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of PharmaCyte Biotech. We use our internally-developed statistical techniques to arrive at the intrinsic value of PharmaCyte Biotech based on widely used predictive technical indicators. In general, we focus on analyzing PharmaCyte Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build PharmaCyte Biotech's daily price indicators and compare them against related drivers.
When running PharmaCyte Biotech's price analysis, check to measure PharmaCyte Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PharmaCyte Biotech is operating at the current time. Most of PharmaCyte Biotech's value examination focuses on studying past and present price action to predict the probability of PharmaCyte Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PharmaCyte Biotech's price. Additionally, you may evaluate how the addition of PharmaCyte Biotech to your portfolios can decrease your overall portfolio volatility.
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance